novo nordisk fda semaglutide wins EU approval for Wegovy weight-loss pill Semaglutide Receives FDA Approval for

Therapeutic Research Protocol Dose: 10 20 mg (= 100200 clicks) Duration: 10 20 days Frequency: Daily or split into two administrations Cycle Interval: 3 6 months off before repeating Goal / Description: Higher-dose schedule explored in longevity and pineal signaling research

Signs that warrant medical attention Severe or persistent vomiting (more than 24 hours or multiple times per day) requires medical evaluation

Generation 2 Tirzepatide (2022 / 2023)

Medical research supports targeted nutritional assessment and individualized lab evaluation, particularly in patients at increased risk of malnutrition or poor intake